Givinostat, a histone deacetylase inhibitor from Italfarmaco, was supported by data from the phase 3 EPIDYS study, a randomized, double-blind, placebo-controlled, multicenter trial investigating the agent vs placebo.
Thanks to this operation, that is subject to the approval of the competition authorities, the Group will reach 1,300 employees in Spain and 3,500 globally, with a consolidated turnover of over 1 billion